Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

Gefitinib Plus Interleukin-2 in Advanced Non-Small Cell Lung Cancer Patients Previously Treated with Chemotherapy

The activation of lymphocytes by gefitinib treatment has been described. In this phase II pilot trial, we explored the possible synergism between IL-2 and gefitinib for non-small cell lung cancer (NSCLC) treatment. From September, 2003, to November, 2006, 70 consecutive patients with advanced, prog...

Full description

Bibliographic Details
Main Authors: Melissa Bersanelli, Sebastiano Buti, Roberta Camisa, Matteo Brighenti, Silvia Lazzarelli, Giancarlo Mazza, Rodolfo Passalacqua
Format: Article
Language:English
Published: MDPI AG 2014-09-01
Series:Cancers
Subjects:
gefitinib
interleukin-2
IL-2
lung cancer
non-small cell lung cancer
NSCLC
immunotherapy
tyrosine kinase inhibitors
TKI
Online Access:http://www.mdpi.com/2072-6694/6/4/2035

Internet

http://www.mdpi.com/2072-6694/6/4/2035

Similar Items